- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combination therapy: the next opportunity and challenge of medicine ; volume:9 ; number:1 ; day:21 ; month:7 ; year:2011 ; pages:1-3 ; date:12.2011
Journal of translational medicine ; 9, Heft 1 (21.7.2011), 1-3, 12.2011
- Creator
-
Ascierto, Paolo A.
- Contributor
-
Marincola, Francesco M.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-9-115
- URN
-
urn:nbn:de:1111-2016041437953
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ascierto, Paolo A.
- Marincola, Francesco M.
- SpringerLink (Online service)
Other Objects (12)
Melanoma: A model for testing new agents in combination therapies
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Lean oncology: a new model for oncologists
The influence of diet on anti-cancer immune responsiveness
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Melanoma: A model for testing new agents in combination therapies
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Lean oncology: a new model for oncologists
The influence of diet on anti-cancer immune responsiveness
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Melanoma: A model for testing new agents in combination therapies
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Lean oncology: a new model for oncologists
The influence of diet on anti-cancer immune responsiveness
Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?